<DOC>
	<DOCNO>NCT00910234</DOCNO>
	<brief_summary>Periventricular leukomalacia ( PVL ) one common brain injury occur preterm infant . Inflammation , hypoxia-ischemia , free oxygen radical formation excitotoxicity know pathogenic mechanism mediate injury . Erythropoietin ( EPO ) show protective hypoxic-ischemic inflammatory injury . During past decade , recombinant human Epo ( rhEpo ) widely use preterm infant prevent treat anemia prematurity , general , rhEpo consider safe well tolerated preterm infant . EPO consider capable pass blood-brain-barrier low dose . Evidence animal experiment reveals rhEpo must give high dos begin within short ( 6 hour ) , critical time period onset brain injury achieve significant neuroprotective effect . A recent study use high-dose rhEpo ( 3000 U rhEpo/kg body weight birth ) neuroprotection preterm infant reveal sign adverse effect early high-dose rhEpo treatment preterm infant identify . Contrary , recent study PVL rat model reveal use low dose rhEpo ( 50-100 U/kg ) effective treatment brain damage induce hypoxia-ischemia affect normal oligodendrocyte maturity . On basis , researcher intent investigate ( 1 ) whether low-dose rhEpo ( 100 U/kg ) high-dose rhEpo ( 3,000 U/kg ) give preterm infant ( gestation age &lt; 32 week ) immediately birth subsequently first 2 day safe posse neuroprotective property ; ( 2 ) whether gender difference response hypoxia-ischemic insult EPO treatment ; ( 3 ) pharmacokinetics low dose high dose rhEPO . Very preterm infant gestational age &lt; 32 week admit NICU eligible enrollment .</brief_summary>
	<brief_title>Recombinant Erythropoietin Neuroprotection Very Preterm Infants</brief_title>
	<detailed_description>Periventricular leukomalacia ( PVL ) one common brain injury occur preterm infant . Inflammation , hypoxia-ischemia , free oxygen radical formation excitotoxicity know pathogenic mechanism mediate injury . Although several treatment strategy devise , therapy effectively mitigate harmful effect hypoxia-ischemia preterm newborn ensue neurodevelopment sequela . Erythropoietin ( EPO ) show protective hypoxic-ischemic inflammatory injury neuronal cell culture , animal model brain injury , clinical trial adult human . During past decade , recombinant human Epo ( rhEpo ) widely use preterm infant prevent treat anemia prematurity , general , rhEpo consider safe well tolerated preterm infant . EPO consider capable pass blood-brain-barrier low dose . Evidence animal experiment reveals rhEpo must give high dos begin within short ( 6 hour ) , critical time period onset brain injury achieve significant neuroprotective effect . A recent study use high-dose rhEpo ( 3000 U rhEpo/kg body weight birth ) neuroprotection preterm infant reveal sign adverse effect early high-dose rhEpo treatment preterm infant identify . Contrary , recent study PVL rat model reveal use low dose rhEpo ( 50-100 U/kg ) effective treatment brain damage induce hypoxia-ischemia affect normal oligodendrocyte maturity . Clinical study suggest gender influence response brain injury . Ment coworkers report cyclooxygenase inhibitor indomethacin ameliorate intraventricular hemorrhage improve cognition low birth weight boy , girl . On basis , researcher intent investigate ( ) whether low-dose rhEpo ( 100 U/kg ) high-dose rhEpo ( 3,000 U/kg ) give preterm infant ( gestation age &lt; 32 week ) immediately birth subsequently first 2 day safe posse neuroprotective property ; ( ii ) whether gender difference response hypoxia-ischemic insult EPO treatment ; ( iii ) pharmacokinetics low dose high dose rhEPO . Very preterm infant gestational age &lt; 32 week admit NICU eligible enrollment . After informed consent obtain , infant randomly assign three group base double-blind design . The study medication ( rhEpo NaCl 0.9 % ) dispense patient number blind clinical investigator . Epoietin Beta equivalent volume normal saline placebo give intravenously period 10 minute 3 6 hour birth , 24 hour interval another 2 doses.The primary short-term outcome measure brain injury ( intraventricular hemorrhage ( IVH ) periventricular leukomalacia ( PVL ) ) ROP . The secondary outcome sepsis , necrotizing enterocolitis ( NEC ) , persistent ductus arteriosus ( PDA ) , apnea prematurity , chronic lung disease . The long term outcomes whether early low-dose high-dose treatment rhEpo preterm infant finally improve neurodevelopmental outcome 24 month ' 5 year ' correct age .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Cerebral Hemorrhage</mesh_term>
	<mesh_term>Retinopathy Prematurity</mesh_term>
	<mesh_term>Leukomalacia , Periventricular</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>After inform consent obtain , preterm infant gestational age &lt; 32 week admit NICU eligible enrollment . Genetically define syndrome , Congenital malformation adversely affect neurodevelopment .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>6 Hours</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Periventricular leukomalacia ( PVL )</keyword>
	<keyword>Erythropoietin ( EPO )</keyword>
	<keyword>Retinopathy prematurity ( ROP )</keyword>
	<keyword>Hypoxia-ischemia</keyword>
</DOC>